Claire Hao

Claire Hao

Auto-generated profile, based on publicly available information

Claire Hao

Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2026 in Neurosurgery
Verified
Journal Article
Closed access
MBMeghana Bhimreddy
Meghana Bhimreddy
Hasan SlikaHasan Slika
Hasan Slika
RJRitvik R. Jillala
Ritvik R. Jillala
PKPatrick Kramer
Patrick Kramer
CHClaire Hao
Claire Hao
NTNicholas Theodore
Nicholas Theodore
BACKGROUND AND OBJECTIVES: Chemotherapeutic drug delivery to intramedullary spinal cord tumors (IMSCTs) is restricted by the blood–spinal cord barrier. Focused ultrasound (FUS), however, can transiently disrupt the blood–spinal cord barrier. Therefore, this study investigates the feasibility of using FUS-enhanced Abraxane (albumin-bound paclitaxel) delivery to improve the treatment of IMSCTs using a rodent model. METHODS: Twenty-eight F344 rats received an intramedullary injection of 100 000 luciferase-tagged 9L gliosarcoma cells. Rats were classified into 4 cohorts: no-treatment, FUS, Abraxane, and FUS-enhanced Abraxane delivery. Treatments were administered on days 7, 14, and 21. Tumor burden was assessed weekly using bioluminescence-based imaging. Twice a week, nociceptive thresholds were assessed using the Von Frey Filament test, and motor function was assessed using the Basso-Beattie-Bresnahan locomotor scale. RESULTS: The FUS-enhanced Abraxane delivery cohort had significantly decreased tumor burden ([1.52 ± 0.69] × 10 6 photons/s) compared with the no-treatment ([9.03 ± 5.13] × 10 6 photons/s), FUS-only ([8.25 ± 1.58] × 10 6 photons/s) and Abraxane-only ([4.19 ± 1.91] × 10 6 photons/s) groups (day 18, P < .0001). Although all rodents initially demonstrated motor decline, the FUS-enhanced Abraxane group had complete return-to-baseline motor scores (21.0) by day 27, whereas the no-treatment (8.3 ± 1.5), FUS-only (6.0 ± 1.4), and Abraxane-only (16.3 ± 1.3) cohorts maintained decreased Basso, Beattie, and Bresnahan scale scores to day 48. Similarly, while all animals demonstrated initial hypersensitivity to pain, only the FUS-enhanced Abraxane group returned to baseline pain response by day 48 (17.4 ± 6.1 g) when compared with the no-treatment (7.0 ± 6.2 g), FUS-only (5.0 ± 1.4 g), and Abraxane-only (11.2 ± 7.5 g) cohorts. CONCLUSION: FUS-enhanced Abraxane delivery significantly reduced IMSCT tumor burden and improved neurological recovery over intravenous administration alone. Therefore, FUS-mediated chemotherapeutic drug delivery may represent a noninvasive, clinically relevant, and effective treatment paradigm for intramedullary pathologies.